UY28868A1 - Ácidos heterociclilacéticos como inhibidores de tafla. - Google Patents

Ácidos heterociclilacéticos como inhibidores de tafla.

Info

Publication number
UY28868A1
UY28868A1 UY28868A UY28868A UY28868A1 UY 28868 A1 UY28868 A1 UY 28868A1 UY 28868 A UY28868 A UY 28868A UY 28868 A UY28868 A UY 28868A UY 28868 A1 UY28868 A1 UY 28868A1
Authority
UY
Uruguay
Prior art keywords
heterociclilacétic
acids
inhibitors
tafla inhibitors
compounds
Prior art date
Application number
UY28868A
Other languages
English (en)
Inventor
Dr Andreas Lindenschmidt
Dr Christopher Kallus
Dr Holger Heitsch
Dr Sven Grueneberg
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34964308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY28868(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of UY28868A1 publication Critical patent/UY28868A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a compuestos de fórmula I que son inhibidores del inhibidor de la fibrinolisis activable por trombina activado. Los compuestos de fórmula I resultan adecuados para producir medicamentos para la profilaxis y terapia de trastornos asociados con trombosis, embolismos, hipercoagulabilidad o cambios fibróticos.
UY28868A 2004-04-22 2005-04-22 Ácidos heterociclilacéticos como inhibidores de tafla. UY28868A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004020186A DE102004020186A1 (de) 2004-04-22 2004-04-22 Heterocyclylessigsäuren als Inhibitoren von TAFla

Publications (1)

Publication Number Publication Date
UY28868A1 true UY28868A1 (es) 2005-11-30

Family

ID=34964308

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28868A UY28868A1 (es) 2004-04-22 2005-04-22 Ácidos heterociclilacéticos como inhibidores de tafla.

Country Status (35)

Country Link
EP (2) EP1740569B1 (es)
JP (1) JP4939401B2 (es)
KR (1) KR101162047B1 (es)
CN (1) CN100572376C (es)
AR (1) AR053302A1 (es)
AT (2) ATE523505T1 (es)
AU (1) AU2005238144B2 (es)
BR (1) BRPI0510159A (es)
CA (1) CA2563401C (es)
CR (1) CR8650A (es)
CY (1) CY1108087T1 (es)
DE (2) DE102004020186A1 (es)
DK (1) DK1740569T3 (es)
EC (1) ECSP066941A (es)
ES (1) ES2299026T3 (es)
HK (1) HK1101823A1 (es)
HR (1) HRP20080099T3 (es)
IL (1) IL178672A (es)
MA (1) MA28543B1 (es)
MY (1) MY140903A (es)
NI (1) NI200600217A (es)
NO (1) NO20065320L (es)
NZ (1) NZ550757A (es)
PE (1) PE20060172A1 (es)
PL (1) PL1740569T3 (es)
PT (1) PT1740569E (es)
RS (1) RS50553B (es)
RU (1) RU2375356C2 (es)
SI (1) SI1740569T1 (es)
TN (1) TNSN06341A1 (es)
TW (1) TWI359016B (es)
UA (1) UA87306C2 (es)
UY (1) UY28868A1 (es)
WO (1) WO2005105781A1 (es)
ZA (1) ZA200607668B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008067909A2 (de) * 2006-12-06 2008-06-12 Sanofi-Aventis Harnstoff- und sulfamidderivate als inhibitoren von tafia
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
US8470863B2 (en) * 2007-02-13 2013-06-25 Merck Sharp & Dohme, Corp. Derivatives and analogs of chroman as functionally selective ALPHA2C adrenoreceptor agonists
JP5489997B2 (ja) * 2007-07-19 2014-05-14 シマベイ セラピューティクス， インコーポレーテッド 糖尿病および代謝疾患の治療のためのＲＵＰ３またはＧＰＲｌ１９受容体のアゴニストとしてのＮ−アザ環状置換ピロール、ピラゾール、イミダゾール、トリアゾールおよびテトラゾール誘導体
EP2262783A2 (en) * 2008-02-21 2010-12-22 Sanofi-Aventis Covalently binding imaging probes
NZ589671A (en) * 2008-06-06 2012-03-30 Sanofi Aventis Macrocyclic urea and sulfamide derivatives as inhibitors of tafia
WO2010050525A1 (ja) 2008-10-29 2010-05-06 大正製薬株式会社 ＴＡＦＩａ阻害活性を有する化合物
RS52963B (en) 2009-05-15 2014-02-28 Sanofi PROCEDURE FOR OBTAINING A COMPOUND USEFUL AS A TAFIA INHIBITOR
FR2947266B1 (fr) * 2009-06-26 2011-06-17 Servier Lab Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2011041154A1 (en) 2009-10-01 2011-04-07 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
CN102803226B (zh) 2010-03-18 2016-05-04 第一三共株式会社 环烷基取代的咪唑衍生物
JP5778133B2 (ja) 2010-03-18 2015-09-16 第一三共株式会社 シクロプロパンカルボン酸誘導体
KR20130130737A (ko) 2010-11-11 2013-12-02 사노피 ３­（６­아미노­피리딘­３일）­２­아크릴산 유도체의 제조방법
WO2013076177A1 (de) 2011-11-25 2013-05-30 Sanofi Salz von (r)-3-(6-amino-pyridin-3-yl)-2-(1-cyclohexyl-1h-imidazol-4-yl)- propionsäureethylester
WO2013076179A1 (en) 2011-11-25 2013-05-30 Sanofi Sodium salt of (r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid
US9145385B2 (en) 2011-11-25 2015-09-29 Sanofi Crystalline salts of R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexy1-1H-imidazol-4-yl)-propionic acid
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
US9834527B2 (en) 2013-06-10 2017-12-05 Sanofi Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals
JPWO2017170460A1 (ja) 2016-03-29 2019-02-07 第一三共株式会社 炎症性腸疾患治療剤
WO2018026890A1 (en) 2016-08-03 2018-02-08 Cymabay Therapeutics Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003013526A1 (en) 2001-08-08 2003-02-20 Merck & Co. Inc. Anticoagulant compounds
JP2005516972A (ja) 2002-01-22 2005-06-09 ファイザー・インク 血栓疾患の治療のためのｔａｆｉ−ａ阻害剤として使用される３−（イミダゾリル）−２−アミノプロピオン酸

Also Published As

Publication number Publication date
ES2299026T3 (es) 2008-05-16
CN100572376C (zh) 2009-12-23
TWI359016B (en) 2012-03-01
PT1740569E (pt) 2008-03-31
NZ550757A (en) 2010-06-25
CA2563401C (en) 2012-08-07
HK1101823A1 (en) 2007-10-26
AU2005238144B2 (en) 2010-08-26
SI1740569T1 (sl) 2008-06-30
AR053302A1 (es) 2007-05-02
CN1950357A (zh) 2007-04-18
RU2006141246A (ru) 2008-06-10
ATE386737T1 (de) 2008-03-15
EP1740569A1 (de) 2007-01-10
EP1864979B1 (de) 2011-09-07
CR8650A (es) 2007-12-04
AU2005238144A1 (en) 2005-11-10
EP1740569B1 (de) 2008-02-20
NO20065320L (no) 2007-01-12
JP2007533672A (ja) 2007-11-22
MA28543B1 (fr) 2007-04-03
RS50553B (sr) 2010-05-07
DK1740569T3 (da) 2008-06-02
UA87306C2 (en) 2009-07-10
KR20070007346A (ko) 2007-01-15
TNSN06341A1 (en) 2008-02-22
CA2563401A1 (en) 2005-11-10
ZA200607668B (en) 2008-03-26
EP1864979A1 (de) 2007-12-12
IL178672A0 (en) 2007-02-11
RU2375356C2 (ru) 2009-12-10
BRPI0510159A (pt) 2007-10-02
WO2005105781A1 (de) 2005-11-10
ECSP066941A (es) 2006-12-20
DE502005002927D1 (de) 2008-04-03
JP4939401B2 (ja) 2012-05-23
PE20060172A1 (es) 2006-03-31
MY140903A (en) 2010-01-29
DE102004020186A1 (de) 2005-11-17
IL178672A (en) 2011-08-31
ATE523505T1 (de) 2011-09-15
KR101162047B1 (ko) 2012-07-04
NI200600217A (es) 2008-06-17
HRP20080099T3 (en) 2008-03-31
TW200602325A (en) 2006-01-16
PL1740569T3 (pl) 2008-07-31
CY1108087T1 (el) 2014-02-12

Similar Documents

Publication Publication Date Title
UY28868A1 (es) Ácidos heterociclilacéticos como inhibidores de tafla.
CO6321271A2 (es) Derivados de urea macrociclicos y de sulfamida como inhibidores de tafla
PH12019501611A1 (en) Chemical compounds as inhibitors of interleukin-1 activity
NI201600071A (es) Compuestos de inhibidor de autotaxina
MX2021001186A (es) Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
BRPI0510777A (pt) indazóis substituìdos, composições que os contêm, processo de produção e utilização
BRPI0514833A (pt) fenilaminotiazóis substituìdos e seu uso
CR20110103A (es) Heteroarilos sustituidos
CO6390069A2 (es) Compuestos de piridina sustituida unida por puente a un heterociclo, como inhibidores de la vía de señalización hedgehog.
GT200900186A (es) Compuestos carboxamida y su uso como inhibidores de calpaína
UY31170A1 (es) Compuestos moduladores de sirtuina
CR10277A (es) Pirazolquinolonas como potentes inhibidores de parp
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
GT201200293A (es) Marcadores predictivos útiles en el tratamiento del síndrome frágil x (fxs)
ATE453670T1 (de) Acrylierte hyaluronsäure
CL2011002911A1 (es) Compuestos derivados de benzamidas, inhibidores de serina proteasa; composición farmacéutica; uso del compuesto para tratar cáncer.
CY1116384T1 (el) Παραγωγα σουλφαμιδιου ως αναστολεις tafia
CL2015002583A1 (es) Composiciones aglomerantes y métodos para fabricación y uso de las mismas.
PE20151669A1 (es) Compuestos de azetidiniloxifenilpirrolidina
ECSP089024A (es) Camsilato de (s)-(-)-amlodipino o hidrato del mismo y composición farmacéutica que comprende el mismo
DOP2007000142A (es) Derivados de urea y derivados de sulfamida en calidad de inhibidores de tafia
UY30760A1 (es) Derivados de urea y derivados de sulfamida en calidad de inhibidores de tafia
BR112017003889A2 (pt) variantes de inibidor de tecido de metaloproteinase tipo três (timp-3), composições e métodos
RU2009104276A (ru) Антиульцерогенное средство
AR060934A1 (es) Uso de un activador de plasminogeno para la manufactura de un medicamento para el tratamiento de tromboembolismo venoso